Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT ID: NCT00401284

Last Updated: 2008-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

135 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating elderly patients diagnosed with primary insomnia who also have moderate daytime sleepiness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Initiation and Maintenance Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EVT 201

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of primary insomnia according to DSM-IV
* Over the last three months for at least 5 nights per week, must have a normal bedtime of between 9 pm and 1 am and a time in bed of at least 7 hours
* A history of sleepiness, tiredness or unintentional napping during the daytime attributed to to poor sleep at night
* Able to attend the Sleep Center for five nights (two consecutive nights on two occasions and one night on one occasion)over a five week period
* Willing and able to complete a sleep diary and questionnaires

Exclusion Criteria

* Clinically significant or unstable medical condition that may interfere with sleep
* Major psychiatric disorders (other than insomnia) such as depression, schizophrenia, bipolar disorder
* History of myocardial infarction, cardiac failure or clinically significant dysrhythmias in the previous 2 years or clinically significant ECG abnormalities at screening
* History of substance abuse
* Disorders that interfere with drug pharmacokinetics
* History of cancer, except basal cell carcinoma
* Use of hypnotics, anxiolytics, antidepressants, anticonvulsants, over-the-counter sleep aids, histamine-1 receptor antagonists (except for loratadine and fexofenadine), beta-adrenergic blockers (except for atenolol), respiratory stimulants and decongestants, systemic steroids, narcotic analgesics, any other compound which might impact sleep-wake function, or medication used for the treatment of Parkinson's disease such as dopamine agonists and L-dopa (e.g., Sinemet, Madopar or Requip)
* Use of hypnotics within the 2 weeks preceding the Screening Period or within five half-lives of the medication, whichever is longer
* Consuming ≥ 350 mg per day of xanthine-containing food or beverages
* Smoking ≥ 10 cigarettes per day and/or unable to refrain from smoking without distress or discomfort for the duration of visits to the sleep laboratory (i.e.≥ 20 hours)
* Body mass index \> 34 kg/m2;
* Performing night work or rotating shift work during the past month
* Traveling across \> 3 time zones in the past 2 weeks
* Participation in another trial of an investigational product or device within the previous 30 days
* Known allergy or sensitivity to benzodiazepines
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Evotec Neurosciences GmbH

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James K Walsh, PhD

Role: PRINCIPAL_INVESTIGATOR

St Luke's Hospital, Sleep Medicine and Research Center, Chesterfield, MI

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

PsyPharma Clinical Research Inc.

Phoenix, Arizona, United States

Site Status

PsyPharma Clinical Research, Inc.

Tucson, Arizona, United States

Site Status

Pacific Sleep Medicine Services Inc

Los Angeles, California, United States

Site Status

Pacific Sleep Medicine Services

San Diego, California, United States

Site Status

Miami Research Associates

Miami, Florida, United States

Site Status

OmniTrials, 11181 Health Park Blvd, Suite 3040

Naples, Florida, United States

Site Status

Broward Research Group

Pembroke Pines, Florida, United States

Site Status

Clinical Research Group of St Petersburg Inc., 2525 Pasadena Ave So, Suite S

St. Petersburg, Florida, United States

Site Status

The Sleep Disorders Center of Georgia, Peachtree Dunwoody Medical Center, 5505 Peachtree Dunwoody Road, Suite 548

Atlanta, Georgia, United States

Site Status

Sleep Disorders Center of Georgia - Gainesville

Gainesville, Georgia, United States

Site Status

Vince and Assocaites Clinical Research

Overland Park, Kansas, United States

Site Status

Community Research

Crestview Hills, Kentucky, United States

Site Status

Center for Sleep Medicine, 101 Courtney Circle

Hattiesburg, Mississippi, United States

Site Status

Sleep Medicine and Research Center, 232 S. Woods Mill Road

Chesterfield (St Louis), Missouri, United States

Site Status

Clinilabs, Inc., 423 West 55th Street, 4th Floor

New York, New York, United States

Site Status

Duke Insomnia and Sleep Research, Duke South Hospital, Room 54242, Trent Drive

Durham, North Carolina, United States

Site Status

Community Research

Cincinnati, Ohio, United States

Site Status

Tri-State Sleep Disorders Center, 1275 East Kemper Road

Cincinnati, Ohio, United States

Site Status

Bradley Hospital Sleep Research Laboratory, 300 Duncan Drive

Providence, Rhode Island, United States

Site Status

Sleep Disorders Center, 1333 Taylor Street, Suite 5A

Columbia, South Carolina, United States

Site Status

Sleep Medicine Associates p.a., 5477 Glen Lakes Drive, Suite 125

Dallas, Texas, United States

Site Status

Baylor College of Medicine, VAMC-Sleep Laboratory, 2002 Holcombe Boulevard , Room 6C-344

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.